1253180-81-2
1253180-81-2
Chemical Structure
Radretumab
- CAS No.: 1253180-81-2
- Formula:
- Molecular Weight:(144.20 kDa)
Biological Activity: Radretumab is a human antibody used for imaging and radioimmunotherapy. Radretumab binds with high affinity to the oncofetal ED-B fibronectin isoform in tumor blood vessels and the extracellular matrix, preferentially localizing to tumor blood vessels without affecting normal tissues. Radretumab can be used in research on brain metastases of solid cancers, teratocarcinoma, and relapsed hematologic malignancies[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Radretumab | 98.56% | Radretumab is a human antibody used for imaging and radioimmunotherapy. Radretumab binds with high affinity to the oncofetal ED-B fibronectin isoform in tumor blood vessels and the extracellular matrix, preferentially localizing to tumor blood vessels without affecting normal tissues. Radretumab can be used in research on brain metastases of solid cancers, teratocarcinoma, and relapsed hematologic malignancies. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Poli GL, et al. Radretumab radioimmunotherapy in patients with brain metastasis: a 124I-L19SIP dosimetric PET study. Cancer immunology research. 2013 Aug;1(2):134-43.
- [2]. Tsai WK, et al. Aligning physics and physiology: Engineering antibodies for radionuclide delivery. J Labelled Comp Radiopharm. 2018 Jul;61(9):693-714.
- [3]. Erba PA, et al. Radioimmunotherapy with radretumab in patients with relapsed hematologic malignancies. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2012 Jun;53(6):922-7.
